Menopause affects every woman who lives long enough to experience it. In South Africa, the average age of natural menopause is around 49–51. The years before (perimenopause) and after are associated with a range of symptoms — hot flushes, sleep disruption, mood changes, vaginal dryness, cognitive fog, and longer-term risks including osteoporosis and cardiovascular disease. Hormone replacement therapy (HRT) is among the most evidence-reviewed treatments in medicine. Yet despite its importance, menopause management is one of the poorest-covered areas in South African medical aids.
What Is Menopause?
Menopause is defined as 12 consecutive months without a menstrual period. It occurs when the ovaries cease producing oestrogen and progesterone in the usual quantities. The average age in SA is around 51, but the process begins 5–10 years earlier — the perimenopause.
Perimenopause: Irregular cycles, fluctuating hormone levels, and onset of vasomotor symptoms (hot flushes, night sweats). Can last 4–10 years before the final menstrual period.
Menopause: The date of the last menstrual period (confirmed retrospectively after 12 months). From this point forward, a woman is post-menopausal.
Post-menopause: Ongoing management of symptoms and long-term health risks — osteoporosis, cardiovascular risk, urogenital atrophy, cognitive health.
Hormone Replacement Therapy (HRT)
HRT is the medical use of oestrogen and/or progestogen to replace what the ovaries no longer produce. It is the most effective treatment for vasomotor symptoms (hot flushes, night sweats) and also provides significant protection against osteoporosis.
Types of HRT:
- Oestrogen-only (for women who have had a hysterectomy): Administered as patches (Estradot, Estrapatch), gels (Oestrogel), or oral tablets (Premarin).
- Combined oestrogen + progestogen (for women with an intact uterus): Oral combined pill (Kliogest, Kliovance, Activelle), patches, or sequential regimens (oestrogen daily + progestogen for 10–14 days/month).
- Tibolone (Livial): A synthetic steroid with oestrogenic, progestogenic, and mild androgenic effects. Often used for combined symptoms including libido.
- Local / vaginal oestrogen: Cream, ring, or pessary applied vaginally for urogenital symptoms. Very low systemic absorption; suitable even for women who cannot take systemic HRT.
- Testosterone (off-label for libido): Testosterone gel (Androgel, Testogel — off-label in women) or compounded preparations. Not SAHPRA-registered for female use; funded inconsistently.
Is Menopause/HRT a PMB or CDL Condition?
No. Menopause and HRT are not PMB conditions and are not on the CDL.
This is the most important coverage fact. Your scheme has no legal obligation to fund HRT or menopause management as a minimum benefit. All costs come from your day-to-day benefits, MSA, or ATB on your plan.
Exceptions: - Osteoporosis (post-menopausal): Osteoporosis is not on the CDL, but fragility fractures requiring hospitalisation are PMB events. DEXA bone density scans may be covered as a preventive benefit on some plans. - If menopause is surgically induced (oophorectomy for cancer): The cancer itself is a PMB condition; HRT prescribed as a consequence of surgical menopause is generally funded as part of the PMB treatment pathway.
How Does Medical Aid Cover Menopause and HRT?
What is typically funded (from day-to-day/MSA/ATB):
| Service | Typical cover | Notes |
|---|---|---|
| GP consultation (menopause assessment) | Yes — day-to-day | |
| Gynaecologist consultation | Yes — day-to-day | Shortfall likely above tariff |
| Blood tests (FSH, LH, oestradiol, thyroid, lipids) | Yes — day-to-day / pathology | |
| DEXA scan (bone density) | Varies | Some plans fund preventive DEXA; others don't |
| Oral HRT (combined or oestrogen-only) | Yes — acute/chronic benefit | Generic options R150–R400/month; brand R400–R900/month |
| Transdermal HRT (patches, gel) | Yes — acute benefit | Brand patches (Estradot 50mcg) ~R300–R500/month |
| Tibolone (Livial) | Yes — acute benefit | ~R400–R600/month |
| Local vaginal oestrogen | Yes — acute benefit | Cream or pessary R200–R400/month |
| Testosterone (off-label) | Varies — scheme discretion | Androgel ~R600–R900/month |
| Psychologist (menopause and mood) | Day-to-day / ATB | Limited sessions; mood disturbance is common |
Day-to-Day Costs: What to Budget For
| Management approach | Estimated annual cost |
|---|---|
| GP-managed HRT (oral generic) | R8,000 – R18,000 |
| Gynaecologist-managed HRT (brand patches + annual DEXA) | R18,000 – R35,000 |
| Complex management (endocrinologist + compounded HRT) | R25,000 – R50,000 |
| Vaginal oestrogen only (local treatment, self-managed) | R3,000 – R8,000 |
Gap Cover Relevance
Gap cover is not relevant for routine menopause management — it covers in-hospital specialist shortfalls, not outpatient consultations or chronic medications. Gap cover would be relevant if: - A surgical procedure is required (e.g., hysteroscopy for abnormal uterine bleeding in perimenopause; endometrial biopsy for postmenopausal bleeding). - Osteoporosis leads to a fragility fracture requiring hospitalisation and surgery.
Key Questions to Ask Your Scheme
- Does my plan include a preventive DEXA scan benefit? Bone density screening is recommended for post-menopausal women at risk of osteoporosis.
- Are HRT prescriptions funded from my chronic benefit or acute/day-to-day benefit? This affects which pool is depleted.
- What is my annual specialist benefit limit? Gynaecologist visits at R1,200–R2,500/visit can deplete a limited specialist sub-limit quickly.
- Does the scheme have a women's health or menopause benefit? Some comprehensive plans (Discovery Health, Momentum) include supplementary women's health benefits.
- Is DEXA funded if I have osteoporosis risk factors? Post-menopausal women with risk factors (low BMI, smoking, family history of fracture, prior fragility fracture) should be screened.
Talk to Eldon
Menopause management is a years-long cost commitment. The difference between a plan with a robust MSA or day-to-day benefit and a plan with depleted day-to-day limits matters significantly for women managing menopause in their 50s and 60s.
See which plans pay for menopause management →